ConvaTec Group

12 days ago · proactiveinvestors.com

JP Morgan has reiterated its 'overweight' rating on ConvaTec Group PLC (LSE:CTEC), saying the medical products group is well positioned to meet its 2026 earnings guidance and that its 2027 outlook is increasingly secure ahead of a trading update next month. A research note ahead of ConvaTec's 10-month trading update on 18 November said the bank had made changes to its divisional growth mix for the second half, while leaving group forecasts largely unchanged.

27 days ago · businesswire.com

LONDON--(BUSINESS WIRE)--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, today released Rethinking leakage in ostomy care, new international research highlighting a significant gap in how peristomal skin health is understood and managed in ostomy care. The findings indicate that skin health plays a critical role in preventing leakage, and supporting confidence in daily life, yet remains widely under-recognised in routi.

1 month ago · businesswire.com

BOSTON & LONDON--(BUSINESS WIRE)--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, announces the launch of Cure Aqua™ in the United States and Canada.The latest addition to Convatec's Cure™ catheter portfolio, Cure Aqua™ is a ready-to-use hydrophilic intermittent catheter designed to support a comfortable catheterization experience while helping simplify daily routines. Developed with direct input from people who cathete.

3 months ago · seekingalpha.com

Convatec Group PLC (CNVVY) Q2 2026 Earnings Call Transcript

3 months ago · marketbeat.com

ConvaTec Group LON: CTEC said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substitute product.

3 months ago · reuters.com

British medical products maker Convatec on Tuesday forecast its second-half operating margin to be materially higher ​than the first half, and pointed to accelerating ‌demand for its infusion care products.